Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001686
Status:
COMPLETED
Last Update Posted:
2020-09-10
First Post:
1999-11-03
Brief Title:
Evaluation Treatment and Natural History of Children and Young Adults With Cancer or Rare Diseases
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Treatment of Children With Cancer
Status:
COMPLETED
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This protocol is designed to evaluate children with cancer who appear to be probable candidates for future protocol entry or have disease manifestations that are of unique scientific importance or educational value
Detailed Description:
Background
Children and adults are referred to the Pediatric Oncology Branch POB for possible enrollment in clinical protocols for the treatment of cancer or other rare diseases While some children are not eligible for a specific protocol they may present with disease manifestations that offer the potential for important new insights into the pathogenesis or clinical behavior of their underlying disease In addition children who have completed participation in a clinical protocol but do not currently have therapeutic protocol alternatives may continue to provide POB with important information Diseases of interest to the POB include but are not limited to lymphoma brain tumors Ewings sarcoma leukemia neuroectodermal tumors osteosarcoma rhabdomyosarcoma RAS-related syndromes and inherited immune disorders amongst others Hence serial clinical evaluation of such patients including the performance of clinical laboratory and diagnostic studies to help elucidate longitudinally the underlying disease mechanisms and when clinically indicated standard care therapies will assist POB meet its overall mission
Objectives
To be able to follow and evaluate children and adults with cancer or pre-cancer syndromes and other rare diseases referred to the Pediatric Oncology Branch who present with disease manifestations that lend themselves to clinical evaluation and are of unique scientific importance
Eligibility
Patients who are evaluated by the Pediatric Oncology Branch and are
Children and adults with cancer or a pre-cancer syndrome or rare disease with disease manifestations of special interest to Pediatric Oncology Branch investigators
Patients must be greater than or equal to 2 years and less than or equal to 40 years of age at the time of study enrollment
Design
The medical procedures or tests will be selected for each patient on the basis of hisher individual diagnosis or presumed diagnosis When clinically indicated standard therapy will be administered and patients will be followed according to standard medical practice Specimens may be collected for clinical care purposes only to evaluate the patient s status No investigational tests drugs or therapies will be administered in this protocol
Children and adults are referred to the Pediatric Oncology Branch POB for possible enrollment in clinical protocols for the treatment of cancer or other rare diseases While some children are not eligible for a specific protocol they may present with disease manifestations that offer the potential for important new insights into the pathogenesis or clinical behavior of their underlying disease In addition children who have completed participation in a clinical protocol but do not currently have therapeutic protocol alternatives may continue to provide POB with important information Diseases of interest to the POB include but are not limited to lymphoma brain tumors Ewings sarcoma leukemia neuroectodermal tumors osteosarcoma rhabdomyosarcoma RAS-related syndromes and inherited immune disorders amongst others Hence serial clinical evaluation of such patients including the performance of clinical laboratory and diagnostic studies to help elucidate longitudinally the underlying disease mechanisms and when clinically indicated standard care therapies will assist POB meet its overall mission
Objectives
To be able to follow and evaluate children and adults with cancer or pre-cancer syndromes and other rare diseases referred to the Pediatric Oncology Branch who present with disease manifestations that lend themselves to clinical evaluation and are of unique scientific importance
Eligibility
Patients who are evaluated by the Pediatric Oncology Branch and are
Children and adults with cancer or a pre-cancer syndrome or rare disease with disease manifestations of special interest to Pediatric Oncology Branch investigators
Patients must be greater than or equal to 2 years and less than or equal to 40 years of age at the time of study enrollment
Design
The medical procedures or tests will be selected for each patient on the basis of hisher individual diagnosis or presumed diagnosis When clinically indicated standard therapy will be administered and patients will be followed according to standard medical practice Specimens may be collected for clinical care purposes only to evaluate the patient s status No investigational tests drugs or therapies will be administered in this protocol
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 98-C-0037 | None | None | None |